Eevia Health Plc

Eevia Health Abp has terminated its arrangement with Mangold Fondkommission as a liquidity provider for its shares on the Spotlight Stockmarket, citing sufficient natural liquidity. For further information, contact CEO Stein Ulve via email at stein.ulve@eeviahealth.com or investor@eeviahealth.com, or by phone at +358 400 22 5967. Eevia Health Plc, established in March 2017, produces bioactive compounds from plant materials, mostly wild-harvested in Finnish and Swedish forests. These extracts are used globally in dietary supplements and food brands. Eevia operates an environmentally friendly production facility in Finland and listed its shares on the Spotlight Stock Market in June 2021 under the ticker EEVIA. For more information, visit www.eeviahealth.com or follow Eevia Health on LinkedIn.

The Annual General Meeting of Shareholders of Eevia Health Plc took place on June 28, 2024, in Seinäjoki, Finland. Key resolutions included: 1. Adoption of the financial statements for 2023, with a net loss of EUR 885,795.22 transferred to retained earnings/loss account, and no dividends to be paid. 2. Discharge granted to the Board of Directors and CEO from liability for the financial year 2023. 3. Re-election of Martin Bjørklund, Per Benjaminsen, Oskar Wegelius, and Patricia Wiklund to the Board of Directors, with Martin Bjørklund as Chairman. 4. Approval of remuneration for the Board: EUR 16,000 for the Chairman and EUR 8,000 for other members, along with option rights for new shares. 5. Re-election of KPMG as auditor, with Mari Kaasalainen as the principal auditor, to be remunerated as per the approved invoice. For more information, contact CEO Stein Ulve at stein.ulve@eeviaheath.com or +358 400 22 5967. Eevia Health Plc, founded in 2017, produces bioactive compounds from wild-harvested plant materials in Finland and Sweden, offering ingredients for dietary supplements and food brands globally. The company emphasizes sustainable practices and operates a green-chemistry production facility. Eevia Health is listed on the Spotlight Stock Market in Sweden. More details are available at www.eeviahealth.com.

Eevia Health Plc has been collaborating with a major international ingredient house over the past year on the global sales of one of its ingredients. A successful feasibility study confirmed the ingredient's safety, and the project is now moving to clinical trials, rebranding, and worldwide commercial rollout. The ingredient house conducted various feasibility investigations, including safety studies, and Eevia has produced multiple industrial-scale batches while providing technical and scientific support. The next steps include initiating human clinical research and a full market launch, with a pre-launch set for May 2025 in some territories. This collaboration is separate from another partnership involving an eye health product. Eevia's CEO, Stein Ulve, highlighted that this opportunity will provide scientific validation and global sales reach for the ingredient, allowing Eevia to focus on other products. Eevia Health was founded in 2017 and specializes in bioactive compounds from wild-harvested plant materials, operating a green-chemistry production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc has received a first sales order worth 188 KEUR (2.1 MSEK) from a large international nutraceutical ingredients company for its Feno-Myrtillus® 25 Organic bilberry extract. This order is the result of an extensive engagement process and signifies Eevia's ability to compete with established brands. The company plans to ship half of the order immediately and the rest within weeks, positively impacting cash flow. The new customer is expected to place repeat orders, enhancing Eevia's market distribution and visibility. Eevia Health, founded in 2017, specializes in organic plant extracts primarily sourced from wild-harvested materials in Finnish and Swedish forests. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.

Eevia Health Plc has received two sales orders totaling 68 KEUR (765 KSEK) from two European customers for its Feno-Myrtillus® organic extracts. One customer is a brand holder selling a bilberry supplement brand across Europe, and the other is an ingredient reseller in France. These repeat orders from stable customers highlight the trust and loyalty towards Eevia's products. The company has bilberry extracts in stock and will ship the orders immediately, positively impacting cash flow. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials in the Finnish and Swedish forests. The company operates a green-chemistry production facility in Finland and listed its shares on the Spotlight Stock Market in Sweden in June 2021. For more information, visit www.eeviahealth.com or follow Eevia Health on LinkedIn.

Eevia Health Plc has received a sales order worth 69 kEUR (780 kSEK) from a new Australian customer for its standardized elderberry extract, Feno-Sambucus 14. The order was facilitated by Eevia's exclusive distributor in Australia, Ingredient Plus, and the end customer is a large contract manufacturing group in Australia with sales across Southeast Asia. This initial order is larger than typical start orders, and the customer is known for large volumes and steady reordering. Eevia expects significant repeat orders from this customer. Feno-Sambucus 14 is an elderberry extract standardized at 14% anthocyanins, differentiated by Eevia's unique purification technology that retains more bioactive compounds compared to competitors. CEO Stein Ulve expressed satisfaction with the success of their Australian distributor and the competitive performance of their European elderberry extracts in Far Eastern markets. Eevia Health Plc, founded in March 2017, produces bioactive compounds from plant materials, primarily wild-harvested from Finnish and Swedish forests. The company sells these extracts B2B as ingredients for dietary supplements and food brands globally. Eevia operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. For more information, visit www.eeviahealth.com or follow Eevia Health on LinkedIn.

Eevia Health Plc has released an information memorandum inviting shareholders to subscribe for new shares. The memorandum, which includes details and instructions for the rights issue, is available on the company's website. If fully subscribed, the offer is expected to raise SEK 28.6 million before expenses. The rights issue is secured by subscription commitments covering 10.8% and guarantee commitments covering 39.4% of the offer volume, totaling 50.2%. Key points of the rights issue include: - Shareholders registered by June 13, 2024, will receive one subscription right per share. - Three subscription rights allow the subscription of four new shares, with one warrant per four subscribed shares. - Subscription starts on June 14, 2024, in Sweden and July 18, 2024, in Finland, ending on June 28, 2024, in Sweden and July 2, 2024, in Finland. - The subscription price is SEK 0.60 per share. - Trading in subscription rights runs from June 14, 2024, to June 25, 2024. Partner Fondkommission and OP Bank are acting as financial advisers and issuing agents in Sweden and Finland, respectively. For more information, contact CEO Stein Ulve or Joel Westerström at Partner Fondkommission. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials for dietary supplements and food brands. The company operates an eco-friendly production facility in Finland and was listed on the Spotlight Stock Market in June 2021. More information can be found on their website.

Eevia Health Plc published a restated Q1 2024 Interim Report due to discrepancies between the 2023 statutory Financial Statements released on June 7 and the 2023 Year-End figures in the Interim Report Q1 2024 published on May 22. These discrepancies arose from accounting adjustments agreed upon with the company's auditor. The adjustments included recognizing revenue of 263 kEUR in January 2024 instead of December 2023, reversing 113 kEUR of product development costs from the balance sheet to the income statement in 2023, and an extraordinary write-down of 426 kEUR in inventory value. As a result of these adjustments, the Q1 2024 figures changed, increasing sales revenues and improving EBITDA for the quarter. Key financial metrics for Q1 2024 include net sales of 671 kEUR, gross profit of 372 kEUR, EBITDA of -103 kEUR, and a net result of -387 kEUR. Cash flow from operations was -254 kEUR. Additionally, Eevia is in discussions for potential collaborations and secured a credit line of 640 kEUR, drawing 265 kEUR in Q1 2024. The company also filed a final report for a business development grant and started negotiations for a contract manufacturing arrangement for 2025. Eevia Health Plc, founded in 2017, produces bioactive compounds from wild-harvested plants, primarily for dietary supplements and food brands. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or follow them on LinkedIn.

Eevia Health Plc has announced the notice for its Annual General Meeting (AGM) of Shareholders, scheduled for June 28, 2024, at its main office in Seinäjoki, Finland. The notice was published on June 10, 2024. The Record date is June 17, 2024, and the deadline for custodians to complete temporary registrations is June 24, 2024, at 10:00 Finnish time. Details on how to participate in the AGM are available in the notice on Eevia Health's website. This information is disclosed in accordance with the EU's Market Abuse Regulation. Eevia Health, founded in 2017, produces bioactive compounds from plant materials, primarily wild-harvested from Finnish and Swedish forests, for use in dietary supplements and food brands globally. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. For more information, contact CEO Stein Ulve.

Eevia Health Plc has reissued the notice for its Annual General Meeting (AGM) scheduled for June 28, 2024, at its main office in Seinäjoki, Finland, due to an incorrect MAR label on the initial notice. The call for the AGM was made on June 10, 2024, with a record date of June 17, 2024, and a market deadline for temporary registrations by custodians on June 24, 2024. The notice and relevant documents are available on the company's website. Eevia Health Plc, founded in 2017, produces bioactive compounds from plant materials for global dietary supplements and food brands. The company is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. For more information, contact CEO Stein Ulve.